CA2993809C — Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
Assigned to Calgent Biotechnology Co Ltd · Expires 2023-09-05 · 3y expired
What this patent protects
The invention relates to new compounds of Formulae (I): Certain disclosed embodiments have low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, certain disclosed compounds may be used in treatment of treating disorders including, but not limite…
USPTO Abstract
The invention relates to new compounds of Formulae (I): Certain disclosed embodiments have low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, certain disclosed compounds may be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.